Le Lézard
Classified in: Health
Subject: FDA

FDA Approves First Medical Implant with New Superalloy


ATLANTA, March 27, 2019 /PRNewswire/ -- MiRus has received FDA 510(k) approval for the MoRe® based Europatm Pedicle Screw System making it the first FDA approved medical device with this new class of implant material.  The Europatm System received the 2018 Spine Technology Award at the NASS meeting for excellence and innovation in spine surgery.

MiRus has developed MoRe®, a proprietary molybdenum rhenium superalloy for medical implants, to provide an unprecedented combination of strength, ductility, durability, and biological safety that is unmatched by current materials.  MoRe® was designed to meet these criteria and is patent protected for use in all medical devices.

The clinical needs of many patients remain unmet due to the limitations of current titanium, cobalt and iron based alloys originally developed more than 40 years ago. The MoRe® superalloy allows for the design of a new generation of smaller, stronger, more durable, and bio-friendly implants that will result in less soft tissue disruption, quicker recovery and better outcomes for patients.

"Spine deformity surgery in adults remains plagued by the poor performance of current implants with rod failure occurring in 18%-20% of patients," noted Munish Gupta MD, Mildred B. Simon Distinguished Professor of Orthopaedic Surgery, Director of Adult/Pediatric Spinal Deformity service and Professor of Neurological Surgery at Washington University, "The MoRe alloy shows great promise in improving the durability of adult spine deformity constructs. This advance will help prevent early revision surgery and improve outcomes in adult deformity surgery in particular."

Peter Newton, MD, Chief of Orthopaedic Surgery at Rady Children's Medical Practice Foundation and Clinical Professor, UCSD observed "I am excited by the excellent material properties of this new alloy and the potential to improve orthopaedic implants."

James Nunley, MD, Goldner Jones Professor of Orthopaedic Surgery at Duke, remarked "This new material with its greater strength, fatigue resistance and superior biological properties will allow us to make lower profile foot and ankle implants leading to smaller surgical exposures and reduced revision rates. "

Jay S. Yadav MD, Founder and CEO of MiRus, stated:

"FDA approval of the Europatm Pedicle Screw System with our patented MoRe® superalloy is the culmination of over ten years of research and development.  Our scientists and engineers working with world class metallurgists have created the greatest advance in medical implant material technology in at least four decades. The MoRe® superalloy will revolutionize many aspects of the medical device industry as the first alloy approved by the FDA for use in an implant which is not based on titanium, cobalt or iron with their inherent limitations.

The FDA requires a rigorous level of scientific investigation to establish the safety and effectiveness of a spine implant that utilizes a new medical alloy. In response to FDA guidance, our scientific team led by Jordan Bauman, VP of Regulatory, developed a comprehensive body of evidence which served as the basis for approval of this major advance in patient care.     

We are fortunate to be collaborating with an outstanding worldwide group of orthopaedic and neurosurgeons in developing transformative spine solutions. Additionally, MiRus is rapidly expanding into other orthopaedic applications such as foot and ankle and has made significant progress in cardiovascular applications of the MoRe® superalloy."

Contact:
Mahesh Krishnan
VP, Sales and Marketing, MiRus
mkrishnan@mirusmed.com
770-317-5564

About MiRus, LLC.
MiRus is a medical device company that has developed and is commercializing proprietary novel biomaterials, implants and software solutions for spine, orthopaedics and cardiovascular disease.  We are addressing the demands of today's healthcare environment with an integrated platform of pre-operative planning and risk assessment tools, a breakthrough navigation and robotics system and post-operative monitoring and risk mitigation. Find more information about MiRus at www.mirusmed.com.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

* MoRe® is a registered trademark of MiRus, LLC.  Europatm and MiRustm are trademarks of MiRus, LLC.

SOURCE MiRus


These press releases may also interest you

6 déc 2019
BrainCo's prosthetic hand won Time Magazine's Top 100 Inventions of the Year. The prosthetic hand represents an advancement in assistive technology, providing amputees with an intuitively controlled prosthetic at a lower cost. ...

6 déc 2019
Helix BioPharma Corp. ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company's annual and special meeting of...

6 déc 2019
In the news release, Delta Dental Invests in Startup to Support Healthy Lifestyles Through Partnership with LEAP's PROPTO InsurTech program, issued 06-Dec-2019 by Delta Dental of Michigan over PR Newswire, we are advised by the company that the...

6 déc 2019
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreements with five investors, including an...

6 déc 2019
SpeakEasy Cannabis Club Ltd.  (the "Company" or "SpeakEasy") is pleased to announce that it has closed its previously announced non-brokered private placement (the "Private Placement") for aggregate gross proceeds of $1,315,000.  The Private...

6 déc 2019
Tosuta International Sales Ltd. is recalling Landers' Australian brand Gluten free Macadamia Shortbread from the marketplace because it contains milk which is not declared on the label. People with an allergy to milk should not consume the recalled...



News published on 27 march 2019 at 10:16 and distributed by: